Research and Development news

Seite:

1

2

1-20 von 28 Dokumente

01/09/12, Research and Development Bayer HealthCare to Share Lab Space with Start-Up Companies Dedicated lab space-model at Bayer HealthCare U.S. Innovation Center to be called CoLaborator™ / Shared lab space will help promising life science companies get their start more

11/09/11, Research and Development Bayer cooperates with Ludwig Boltzmann Institute for Translational Heart Failure Research Newly founded institute studies the causes of heart failure and seeks new therapeutic options more

10/26/11, Research and Development Phase III Trial of Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival Trial stopped based on positive data from a pre-planned interim analysis more

09/24/11, Research and Development Positive Phase III Data on Bayer’s Investigational Drug Alpharadin Show Significant Increase in Overall Survival First presentation of full data as part of Presidential Session featuring best and late-breaking abstracts at 2011 European Multidisciplinary Cancer Congress more

06/30/11, Research and Development Bayer advances research in the area of pulmonary hypertension Cooperation with the Ludwig Boltzmann Institute for Lung Vascular Research / The aim is to develop new treatment options for patients with pulmonary hypertension more

04/05/11, Research and Development In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit MAGELLAN study meets primary efficacy endpoints of demonstrating non-inferiority in short-term use and superiority in long-term use / Primary analysis shows no consistent positive benefit-risk balance across heterogeneous patient population studied more

04/01/11, Research and Development Bayer to Present Data on Oncology Pipeline First Presentation of Preclinical Data Evaluating Innovative Compounds, Mechanisms and PET Tracers / Presentations Highlight Growing Research and Portfolio more

03/11/11, Research and Development OncoTrack: A new International consortium launches project in the area of genomic cancer diagnostics International consortium of over 60 scientists is managed by Bayer HealthCare Pharmaceuticals and the Max Planck Institute for Molecular Genetics more

01/11/11, Research and Development New Bayer U.S. Innovation Center starts its operations Laboratories and offices located in San Francisco’s Mission Bay life sciences hub / Master agreement between Bayer and University of California, San Francisco (UCSF) signed more

01/10/11, Research and Development Bayer Initiates Phase III Trial of Regorafenib in Metastatic or Unresectable Gastrointestinal Stromal Tumors more

12/17/10, Research and Development FDA approves Bayer’s new oral contraceptive Safyral™ Oral contraceptive raises folate levels, reducing the risk of neural tube defects more

12/13/10, Research and Development Bayer: 35 million Euros for the expansion of the development of biologicals more

12/10/10, Research and Development New oral contraceptive regimen submitted for marketing authorization in the EU Will support women in managing their menstrual cycle individually / Minimizes the number of bleedings / Innovative device, supporting women to follow an individualized intake regimen more

11/22/10, Research and Development Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration In both studies, all regimens of VEGF Trap-Eye, including VEGF Trap-Eye dosed every two months, achieved primary endpoint compared to ranibizumab dosed every month / Regulatory applications for marketing approval planned in first-half of 2011 more

10/11/10, Research and Development EU regulators okay Qlaira® for the treatment of heavy menstrual bleeding more

10/08/10, Research and Development Bayer to Present Early Clinical Data on Two Phase III Compounds in Company’s Oncology Pipeline at ESMO 2010 Data on AlpharadinTM (radium-223 chloride) and regorafenib (BAY 73-4506) to be presented more

10/07/10, Research and Development Bayer and Onyx Announce Nexavar® Data Presentations at 2010 ESMO Congress more

10/07/10, Research and Development Bayer’s Xarelto® Recognised with 2010 International Prix Galien Award more

09/27/10, Research and Development Bayer receives approval for Beyaz® in the U.S. First and only contraceptive to raise folate levels, reducing the risk of neural tube defects / First and only FDA-approved birth control pill with four indications more

09/06/10, Research and Development LEVITRA 10mg Orodispersible Tablet for the Treatment of Erectile Dysfunction approved in Europe New formulation expected to be launched in November 2010 more

Seite:

1

2

1-20 von 28 Dokumente

More information about the topic Research and Development: